Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04003454 · ClinicalTrials.gov registry record · NA
The DETECT HCV Screening Trial
A NA study of Hepatitis C, sponsored by Denver Health and Hospital Authority.
- Completed
- Registry status
- NA
- Development phase
- 147,533
- Enrollment target
- 3
- Study locations
NCT04003454: Completed NA study of Hepatitis C, sponsored by Denver Health and Hospital Authority.
NCT04003454 is a NA study of Hepatitis C that has completed, run by Denver Health and Hospital Authority. The registered enrollment target is 147,533 participants, above the 498-participant average among 106 other Hepatitis C trials with a reported enrollment target (29525% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04003454, a NA study of Hepatitis C, has completed, sponsored by Denver Health and Hospital Authority.
- COMPLETED
- Registry status
- NA
- Development phase
- 147,533 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators propose to compare the effectiveness of nontargeted rapid opt-out hepatitis C (HCV) screening versus targeted rapid opt-out HCV screening using recommended risk characteristics in multiple urban emergency departments (EDs) across the United States (Aim 1 - "Screening Trial").
Primary Outcome
Confirmed cases of newly diagnosed active HCV, defined as patients who test positive for HCV antibody and measurable HCV RNA, and without a prior HCV diagnosis, stratified by study arm
Conditions Studied
Interventions
- OTHER HCV Screening
Study Locations (3)
Colorado
- Denver Health Medical Center - Denver
Maryland
- Johns Hopkins University - Baltimore
Mississippi
- University of Mississippi Medical Center - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147,533 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2024-01-31 |
| Phase | NA |
What the finished NCT04003454 record still lists
NCT04003454 is an interventional study that assigns participants to a tested intervention. Its 147,533 participants enrollment target places it among the larger protocols in the corpus, above the 498-participant average among 106 other Hepatitis C trials with a reported enrollment target (29525% higher).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which HCV Screening is the first listed.
NCT04003454 reports a single indexed study location in Colorado, Maryland, Mississippi.
Frequently Asked Questions
What is clinical trial NCT04003454 about?
NCT04003454 is a clinical study titled "The DETECT HCV Screening Trial". The investigators propose to compare the effectiveness of nontargeted rapid opt-out hepatitis C (HCV) screening versus targeted rapid opt-out HCV screening using recommended risk characteristics in multiple urban emergency departments (EDs) across the United States (Aim 1 - "Screening Trial").
What is the current status of trial NCT04003454?
This trial is currently completed. It is a NA study. The enrollment target is 147,533 participants. The study started on 2019-11-20. Estimated completion is 2024-01-31.
What conditions does trial NCT04003454 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT04003454?
The interventions under investigation include: HCV Screening (OTHER).
Who is sponsoring clinical trial NCT04003454?
This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04003454 being conducted?
This trial has 3 study locations across Colorado, Maryland, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04003454's enrollment target sits among peer trials
147,533 1st of 106 higher than 106 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
RECRUITING · NA
-
HCV Tappt Adherence Study
RECRUITING · NA
-
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
RECRUITING · NA
-
Buprenorphine Integration Research and Community Health
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI